PharmacoEconomics

Acknowledgment
pp. 975-977(3)

Swimming Upstream: Comparative Effectiveness Research in the US
pp. 979-982(4)
Author: Greene, Jeremy A.

Weighting Must Wait: Incorporating Equity Concerns into Cost-Effectiveness Analysis May Take Longer than Expected
pp. 983-989(7)
Authors: Wailoo, Allan; Tsuchiya, Aki; McCabe, Christopher

Cost Effectiveness of Herpes Zoster Vaccine in Canada
pp. 991-1004(14)
Authors: Najafzadeh, Mehdi; Marra, Carlo A.; Galanis, Eleni; Patrick, David M.

Willingness to Pay for a QALY Based on Community Member and Patient Preferences for Temporary Health States Associated with Herpes Zoster
pp. 1005-1016(12)
Authors: Lieu, Tracy A.; Ray, G. Thomas; Ortega-Sanchez, Ismael R.; Kleinman, Ken; Rusinak, Donna; Prosser, Lisa A.

Bayesian Modelling of Healthcare Resource Use in Multinational Randomized Clinical Trials
pp. 1017-1029(13)
Authors: Gauthier, Aline; Manca, Andrea; Anton, Susan

Healthcare Costs and Obesity Prevention: Drug Costs and Other Sector-Specific Consequences
pp. 1031-1044(14)
Authors: Rappange, David R.; Brouwer, Werner B.F.; Hoogenveen, Rudolf T.; Van Baal, Pieter H.M.

Accounting for the Development of Antibacterial Resistance in the Cost Effectiveness of Ertapenem versus Piperacillin/Tazobactam in the Treatment of Diabetic Foot Infections in the UK
pp. 1045-1056(12)
Authors: Jansen, Jeroen P.; Kumar, Ritesh; Carmeli, Yehuda